Clinical Trial Search

Primary: Percentage of Participants With Antibody Titers >=1:8 Against Meningococcal Serogroups A, C, W, and Y Measured by hSBA Following Vaccination With MenACYW Conjugate…

Primary: Progression Free Survival by Independent Response Adjudication Committee (IRAC) — 11.20; 7.10 Months — p=0.001

Primary: Number of Participants With Treatment-Emergent Adverse Events — 221 Participants

Primary: Patients' Adherence to Study Protocol — 22; 24; 19; 19 Participants

Primary: AUC (0-7): Area Under the Concentration Time Curve Over a Dosing Interval of Either Every 3 Weeks [AUC0-21 Days] or Every 4 Weeks [AUC0-28 Days] for Total Immunoglobulin…

Primary: The Mean Percent Improvement From Baseline in PASI Score at Week 12 — 77.93; 75.89 percentage of improvement in PASI score

Primary: Phase II: Relative Change From Baseline in Oxygenation Index in Supine Position at Day 5 (FAS) — 15.5; 31.9 percentage of change — p=0.3677

Primary: Change From Baseline in the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) Total Score — -5.91; -4.91 Scores on a scale — p=0.2202

Primary: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Fatigue Subscale Score — 4.00; 7.00; 8.50; 5.00 score on a scale — p=0.16

Primary: OMERACT-OARSI Responder Rate at 39 Weeks — 91.2; 92.4; 93.2 Percentage of subjects — p=0.8106

Primary: The Proportion of Subjects With Investigator Global Assessment Mod 2011 (Scalp) Score of "Clear" and "Almost Clear" With at Least 2-point Reduction From Baseline at Week…

Primary: Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose — 121; 190 Participants — p=<.0001

Primary: Number of Participants With Relapse — 7 Participants

Primary: Number of Participants With Successful Anesthesia Induction — 163; 81 Participants

Primary: Overall Response Rate (ORR) (Assessed by Independent Review Committee [IRC]) — 73 percentage of participants